View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 14, 2022

Innoviva agrees to sell stake in Theravance Respiratory Company

TRC also transferred its ownership stakes in InCarda Therapeutics, ImaginAb, Gate Neurosciences, and Nanolive to Innoviva.

Innoviva has signed an agreement for the sale of its 15% economic stake in Theravance Respiratory Company (TRC) to Royalty Pharma for nearly $282m in upfront cash payments and a potential contingent sales-based milestone payment of $50m.

TRC receives royalties generating from sales of TRELEGY ELLIPTA (the combination FF/UMEC/VI).

According to the agreement, TRC also transferred all of its ownership stakes and investments in InCarda Therapeutics, ImaginAb, Gate Neurosciences, and Nanolive to Innoviva .

With respect to its respiratory assets ANORO ELLIPTA and RELVAR/BREO ELLIPTA, Innoviva retained its royalty rights.

The sale is expected to close this month.

Innoviva CEO Pavel Raifeld said: “We are very pleased to have entered into this agreement with Royalty Pharma, a market leader in healthcare royalty acquisitions.”

“This transaction allows us to capture an attractive valuation for our share of TRELEGY ELLIPTA economics, enhances our cash position at a time of meaningful market dislocations, and demonstrates our continued commitment to leaving no stone unturned in our efforts to maximise shareholder value.

“We look forward to continuing our long-standing collaboration with GSK for RELVAR/BREO ELLIPTA and ANORO ELLIPTA.”

Prior to this development, Innoviva signed a definitive merger agreement to acquire all of the outstanding shares of La Jolla Pharmaceutical Company for an enterprise value of nearly $149m, through its wholly owned subsidiary.

Concurrently, Theravance Biopharma entered a transaction to sell its economic interest of 85% in TRC to Royalty Pharma.

Innoviva , Theravance Biopharma and GSK signed a customary release of claims with regard to conduct before the closing.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology